Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.
2.

Generic substitution: issues for problematic drugs.

Henderson JD, Esham RH.

South Med J. 2001 Jan;94(1):16-21. Review. Erratum in: South Med J. 2001 Dec;94(12):1235.

PMID:
11213935
3.

Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.

Bialer M, Midha KK.

Epilepsia. 2010 Jun;51(6):941-50. doi: 10.1111/j.1528-1167.2010.02573.x. Epub 2010 Apr 8. Review.

4.

Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J.

Ann Pharmacother. 2009 Oct;43(10):1583-97. doi: 10.1345/aph.1M141. Epub 2009 Sep 23.

PMID:
19776300
5.

Wellbutrin versus generic bupropion.

[No authors listed]

Med Lett Drugs Ther. 2008 Jul 14;50(1290):54-5. No abstract available.

PMID:
18617874
6.

United States Food and Drug Administration requirements for approval of generic drug products.

Meyer MC.

J Clin Psychiatry. 2001;62 Suppl 5:4-9; discussion 23-4. Review.

7.

Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.

Liu Q, Davit BM, Cherstniakova SA, Dandamudi S, Walters JF, Lee CH, Raines KW, Ren K, Williamson LN, Conner DP.

AAPS J. 2012 Mar;14(1):19-22. doi: 10.1208/s12248-011-9312-7. Epub 2011 Dec 1.

8.
9.

Evaluating the bioavailability and bioequivalence of generic medications.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2010 Jan;48(1):13-6. doi: 10.3928/02793695-20091204-07.

PMID:
20102127
10.

Withdrawal of generic budeprion for nonbioequivalence.

Woodcock J, Khan M, Yu LX.

N Engl J Med. 2012 Dec 27;367(26):2463-5. doi: 10.1056/NEJMp1212969. Epub 2012 Dec 5. No abstract available.

11.

[The clinical and economic impact of generic drugs in the treatment of epilepsy].

Argumosa A, Herranz JL.

Rev Neurol. 2005 Jul 1-15;41(1):45-9. Spanish.

12.

Current approaches to the use of generic antiepileptic drugs.

Krämer G, Biraben A, Carreno M, Guekht A, de Haan GJ, Jedrzejczak J, Josephs D, van Rijckevorsel K, Zaccara G.

Epilepsy Behav. 2007 Aug;11(1):46-52. Epub 2007 May 29. Review.

PMID:
17537678
14.

Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.

Kesselheim AS, Polinski JM, Fulchino LA, Isaman DL, Gagne JJ.

Drugs. 2015 Apr;75(6):633-50. doi: 10.1007/s40265-015-0382-1. Review.

PMID:
25822610
15.

A review of the safety of generic drugs.

Dighe SV.

Transplant Proc. 1999 May;31(3A Suppl):23S-24S. Review.

PMID:
10330955
16.

Interchangeability, Safety and Efficacy of Modified-Release Drug Formulations in the USA: The Case of Opioid and Other Nervous System Drugs.

Seoane-Vazquez E, Rodriguez-Monguio R, Hansen R.

Clin Drug Investig. 2016 Apr;36(4):281-92. doi: 10.1007/s40261-015-0374-7.

PMID:
26818406
17.

Drug substitution in transplantation: a National Kidney Foundation White Paper.

Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH.

Am J Kidney Dis. 1999 Feb;33(2):389-97. Review.

PMID:
10023656
18.

Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.

Karalis V, Macheras P, Bialer M.

CNS Drugs. 2014 Jan;28(1):69-77. doi: 10.1007/s40263-013-0112-8.

PMID:
24092569
19.

Generic drug product equivalence: current status.

Meyer MC.

Am J Manag Care. 1998 Aug;4(8):1183-9; quiz 1190-2.

20.

Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants.

Alloway RR, Isaacs R, Lake K, Hoyer P, First R, Helderman H, Bunnapradist S, Leichtman A, Bennett MW, Tejani A, Takemoto SK.

Am J Transplant. 2003 Oct;3(10):1211-5.

Supplemental Content

Support Center